Alma íbúðafélag hf.: Ársreikningur 2024
Á fundi sínum í dag samþykkti stjórn Ölmu íbúðafélags hf. ársreikning samstæðunnar fyrir árið 2024. Leigutekjur samstæðunnar námu 5.160 m. kr. og aðrar rekstrartekjur námu 541 m. kr. Heildartekjur samstæðunnar…
Valoe jatkaa vaihtovelkakirjalainan 1/2023 merkintäaikaa
Valoe Oyj Pörssitiedote 28.2.2025 klo 19.55 Valoe Oyj:n hallitus on päättänyt jatkaa 14.7.2023 julkistetun Vaihtovelkakirjalainan 1/2023 merkintäaikaa siten, että merkintäaika päättyy 31.3.2025 klo 18.00. Mikkelissä 28. päivänä helmikuuta 2025 Valoe…
Valoe Extends the Subscription Period of the Convertible Bond 1/2023
Valoe Corporation Stock Exchange Release 28 February 2025 at 19.55 Finnish time The Board of Directors of Valoe Corporation has resolved to extend the subscription period of the Convertible Bond…
Aðalfundur Hampiðjunnar hf.
Aðalfundur Hampiðjunnar hf. verður haldinn að Skarfagörðum 4, Reykjavík, föstudaginn 21. mars 2025 og hefst klukkan 16:00. Á dagskrá fundarins verður: 1. Skýrsla stjórnar félagsins um starfsemina árið 2024. 2.…
Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 26 02 2025]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Form 8.3 – [ALLIANCE PHARMA PLC – 26 02 2025]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Closure of the Company’s offer
Albion Enterprise VCT PLC LEI Code 213800OVSRDHRJBMO720 Closure of the Company’s offer under the Albion VCTs Prospectus Top Up Offers 2024/2025 (the “Offers") The Board of Albion Enterprise VCT PLC…
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies.The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood Advances.A key step…
Colabor Group Reports Results for the Fourth Quarter and Fiscal 2024
SAINT-BRUNO-DE-MONTARVILLE, Quebec, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) reports its results for the fourth quarter and fiscal year ended December 28,…
Groupe Colabor dévoile ses résultats du quatrième trimestre et de l’exercice 2024
SAINT-BRUNO-DE-MONTARVILLE, Québec, 25 févr. 2025 (GLOBE NEWSWIRE) -- Groupe Colabor Inc. (TSX : GCL) (« Colabor » ou la « Société »), divulgue ses résultats pour le quatrième trimestre et…